Cell therapy (CAR-T) · Kills target cells, directed at T-cell receptor beta constant 1 (TRBC1) (TRBC1) · developed by Autolus
AUTO4 is an autologous T-lymphocyte cell therapy engineered to express a chimeric antigen receptor with an anti-TRBC1 single chain variable fragment, the 4-1BB co-stimulatory domain and the CD3-zeta signaling chain. It binds TRBC1 on tumor cell surfaces, leading to lysis of TRBC1-expressing cells, and carries the RQR8 off switch that allows selective removal of the T cells with rituximab. It is studied in T-cell non-Hodgkin lymphomas, including peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03590574 | Phase 1/2 | T Cell Non-Hodgkin Lymphoma | Terminated | AUTL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedT Cell Non-Hodgkin Lymphoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the AUTL page.
See AUTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AUTL catalysts and pipeline →